hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

rney Docket No.: 015280-371100US Client Reference No.: E-230-1998/0-US-

Commissioner for Patents O. Box 1450 Álexandria, VA 22313-1450

January 14, 20035

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RYBAK and NEWTON

Application No.: 09/807,556

Filed: July 30, 2001

For: SELECTIVE TOXICITY OF AMINO-TERMINAL MODIFIED RNASE A SUPERFAMILY

POLYPEPTIDES

Examiner: Kagnew H. Gebreyesus

Art Unit: 1652

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

61/21/2002 YPELATI 00000017 201470 67107225

01 7386668

100.00 02

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the

information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses

all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or

Notice of Allowance.

CERTIFICATION

I hereby certify that each item of information contained in this Information

Disclosure Statement was first cited in any communication from a foreign patent office in a

counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that there is an \$180 fee for submission of this statement. The

Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-

1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted

Deposit Account. This letter is submitted in duplicate.

Respectfully submitted,

Chuan Gao

Reg. No. 54,111

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200

Fax: 415-576-0300

CG:ack

60384796 v1

		100 041
PIU	/SB/21	(09-04)

			0/38/21 (05-0-)
	Application Number	09/807,556	
TRANSMITTAL	Filing Date	July 30, 2001	
Me ' 8 225 TFORM	First Named Inventor	Susanna, Rybak M.	
	Art Unit	1652	
Total Number of Pages in This Submission	Examiner Name	Kagnew H. Gebreyesus	
Total Number of Pages in This Submission	Attorney Docket Number	015280-371100US	

Total Number of I	Pages in This Submission	n	Attorney Docke	et Number	015280-37110	00US	
ENCLOSURES (Charle all that apply)							
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement with PTO/SB/08B			Terminal Disclain Request for Ref	ert to a lication ey, Revocation espondence Addre imer und CD(s)	SS Aft Ap Of Ap (Ap (Ap CAP	peal Com Appeals a peal Com peal Notic oprietary atus Lette her Enclo low): copy of I erences A	munication to Board and Interferences immunication to TC ce, Brief, Reply Brief) Information er esure(s) (please identify DS for fee authorization; AA-AU; Return Postcard
Firm Name	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Signature	(° - (-) -	-6					
Printed name	Chuan Gao						
Date 1/14-/05			Reg. No.	54,111			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.							
Signature	Signature Cu L L						
Typed or printed in						1/14/05	

Substitute for form 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (use as many sheets as necessary)

Sheet

Complete if Known					
Application Number	09/807,556				
Filing Date	July 30, 2001				
First Named Inventor	Susanna, Rybak M.				
Art Unit	1652				
Examiner Name	Kagnew H. Gebreyesus				
Attorney Docket Number	015280-371100US				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BEINTEMA, J., et al., "Amino Acid Sequence of the Nonsecretory Ribonuclease of Human Urine," Biochemistry, 1988, pp. 4530-4538, Vol. 27, American Chemical Society.	
	AB	BEINTEMA, et al., "Molecular Evolution of the Ribonuclease Superfamily," <u>Prog. Biophys. Mol. Biol.</u> , 1988, p. 165-190, Vol. 51.	
	AC	BEINTEMA, J., et al., "The Ribonuclease A Superfamily: general discussion," <u>Cell Mol. Life Sci.</u> , 1998, pp. 825-832, Vol. 54.	
	AD	BOIX, E., et al., "Role of the N Terminus in RNase a Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity," <u>J. Mol. Biol.</u> , 1996, pp. 992-1007, Vol. 257, Academic Press Limited.	
	AE	CARA, A., et al., "Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector," <u>Gene Therapy</u> , 1998, pp. 65-75, Vol. 5, Stockton Press.	
	AF	FODSTAD, et al., "Phase I Study of the Plant Protein Ricin," Cancer Res., 1984, p. 862, Vol. 44.	
	AG	GRIFFITHS, S., et al., "Ribonuclease inhibits Kaposi's sarcoma," Nature, December 11, 1997, p. 568, Vol. 390.	
	АН	GULLBERG, et al., "The Cytotoxic Eosinophil Cationic Protein (ECP) Has Ribonuclease Activity," Biophys. Biochem. Res. Comm., 1986, pp. 1239-1242, Vol. 139, No. 3, Academic Press, Inc.	
	Al	LUNARDI-ISKANDAR, Y., et al., "Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease," Nature Medicine, April 1998, pp. 428-434, Vol. 4, No. 4.	
• • • • • • • • • • • • • • • • • • • •	AJ	NEWTON, D.L., et al., "Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy," <u>Protein Eng.</u> , 1997, pp. 463-470, Vol. 10, Oxford University Press.	
	AK	NEWTON, D.L., et al., "Single Amino Acid Substitutions at the N-Terminus of a Recombinant Cytotoxic Ribonuclease Markedly Influence Biochemical and Biological Properties," <u>Biochemistry</u> , 1998, pp. 5173-5183, Vol. 37, American Chemical Society.	
	AL	PREUSS, et al., "Cloning of cDNA encoding the complete precursor for bovine seminal ribonuclease," Nuc. Acids. Res., 1990, p. 1057, Vol. 18, Oxford University Press.	
	АМ	ROSENBERG, H., et al., "Molecular cloning of the human eosinophil-derived neurotoxin: A member of the ribonuclease gene family," Proc. Natl. Acad. Sci. USA , June 1989, p. 4460, Vol. 86	
	AN	ROSENBERG, et al., "Human Eosinophil Cationic Protein: Molecular Cloning of a Cytotoxin and Helminthotoxin with Ribonuclease Activity," <u>J. Exp. Med.</u> , July 1989, p. 163-176, Vol. 170, The Rockefeller University Press.	
	AO	ROSENBERG, et al., "Eosinophil Cationic Protein and Eosinophil-derived Neurotoxin: Evolution of Novel Function in a Primate Ribonuclease Gene Family," <u>J. Biol. Chem.</u> , 1995, pp. 21539-21544, Vol. 270, No. 37, USA.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	or form 1449	B/PTO		Complete if Known		
		0 1 D 10	01.001105	Application Number	09/807,556	
INFORMATION DISCLOSURE				Filing Date	July 30, 2001	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Susanna, Rybak M.	
				Art Unit	1652	
(use as many sheets as necessary)			necessary)	Examiner Name	Kagnew H. Gebreyesus	
Sheet	T1	of	2	Attorney Docket Number	015280-371100US	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	AP	RYBAK, S.M., et al., "RNase and RNase immunofusions for cancer therapy," <u>Tumor Targeting</u> , 1995, pp. 141-147, Vol. 1.					
	AQ	SAKAKIBARA, R., et al., "A Putative Mouse Oocyte Maturation Inhibitory Protein from Urine of Pregnant Women: N-Terminal Sequence Homology with Human Nonsecretory Ribonuclease," Chem. Pharm. Bull., 1991, pp. 146-149, Vol. 39., No. 1, Pharmaceutical Society of Japan.					
	AR	SLIFMAN, et al., "Ribonuclease Activity Associated with Human Eosinophil-Derived Neurotoxin and Eosinophil-Derived Neurotoxin and Eosinophil Cationic Protein," J. Immunol. Comm., 1986, pp. 2913-2917, Vol. 137, No.9, The American Association of Immunologists, USA.					
	AS	TITANI, et al, "Amino Acid Sequence of Sialic Acid Binding Lectin from Frog (Rana catesbeiana) Eggs," <u>Biochemistry</u> , 1987, p. 2189, Vol. 26, the American Chemical Society.					
	AT	YOULE, R., et al., "Cytotoxic Ribonucleases and Chimeras in Cancer Therapy," <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> , 1993, pp. 1-28, Vol. 10, No. 1, CRC Press, Inc.					
	AU	ZEWE, et al., "Cloning and cytotoxicity of a human pancreatic RNase immunofusion," <u>Immuno Technology</u> , pp. 127-136, Vol. 3, Elsevier Science B.V.					

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.